Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ratutrelvir

Small molecule · Inhibitor of SARS-CoV-2 main protease (Mpro, 3CL) · developed by Traws Pharma

Phase 2 Most advanced trial
TRAW Developer
1 Registered trials

What is Ratutrelvir?

Ratutrelvir (83-0060) is a covalent inhibitor of the SARS-CoV-2 main protease (Mpro, also called 3CL). It is being studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
SARS-CoV-2 main protease (Mpro, 3CL)
Mechanism
Inhibitor of SARS-CoV-2 main protease (Mpro, 3CL)
Therapy area
Infectious disease
Developer
Traws Pharma, Inc. (TRAW)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
VR2S5588W2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07157007 Phase 2 COVID - 19 Completed TRAW

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID - 19

More from Traws Pharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TRAW page.

Follow TRAW, the company behind Ratutrelvir

See TRAW's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TRAW catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.